Radium-223 as an Approved Modality for Treatment of Bone Metastases
| Autor: | Elba Etchebehere, Ana Emília Brito |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Radium-223
Male medicine.medical_specialty Nausea Anemia Bone Neoplasms Neutropenia 030218 nuclear medicine & medical imaging 03 medical and health sciences Prostate cancer 0302 clinical medicine Spinal cord compression medicine Humans Radiology Nuclear Medicine and imaging Bone pain Drug Approval Modality (human–computer interaction) business.industry medicine.disease Prostatic Neoplasms Castration-Resistant 030220 oncology & carcinogenesis Isotope Labeling Radiology medicine.symptom business medicine.drug Radium |
| Zdroj: | Seminars in nuclear medicine. 50(2) |
| ISSN: | 1558-4623 |
| Popis: | Radium-223 dichloride (223Ra) is an α-emitter radionuclide approved for treatment of osteoblastic metastases in castrate-resistant prostate cancer (mCRPC) patients. 223Ra increases overall survival, improves bone pain, increases the median time to the first skeletal-related event, reduces the use of external beam radiation therapy for bone pain palliation, reduces the rates of spinal cord compression, and hospitalization. 223Ra therapy has minimal side effects; the most common hematological side effects are anemia, thrombocytopenia and neutropenia while the nonhematological side effects that may occur are bone pain flare, nausea, fatigue, and diarrhea. Alongside 223Ra therapy there are currently a variety of first-line therapeutic options available to treat mCRPC patients and much debate regarding the appropriate treatment algorithm for these patients and the possible combination of therapies among the ones available. In this article, we review the rationale behind 223Ra therapy as well as 223Ra mechanisms of action, biodistribution and dosimetry, optimal timing possibilities to initiate 223Ra in contrast to other treatments available, the association of 223Ra with other therapies and the means of evaluating patients in order to properly deliver to 223Ra therapy. Furthermore, we will discuss 223Ra dose administration possibilities, patient and dose preparation and the challenges of treatment response evaluation during and after 223Ra. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect